You are here

A simple assay system for rapid detection of circulating tumor cells

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA183428-01A1
Agency Tracking Number: R41CA183428
Amount: $330,708.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-25
Award End Date (Contract End Date): 2017-06-30
Small Business Information
1281 WIN HENTSCHEL BLVD., West Lafayette, IN, 47906-4182
DUNS: 832280569
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 BIN HONG
 (502) 445-6362
 friendsensor@gmail.com
Business Contact
 BIN HONG
Phone: (502) 445-6362
Email: friendsensor@gmail.com
Research Institution
 METHODIST HOSPITAL (HOUSTON, TX)
 6565 FANNIN ST, MS# M101
HOUSTON, TX, 77030-2703
 Domestic nonprofit research organization
Abstract
DESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate Accurate detection of CTCs will provide critical information for proper management of cancer patients Currently the CellSearch R test is the only FDA approved method for detection of CTCs in cancer patient blood However similar to all other antibody mediated methods this test requires multiple steps for sample preparation and cell labeling which can cause loss of and damage to CTCs in blood samples and adversely affect the sensitivity and accuracy of the test In addition the requirement of multiple steps is time and labor consuming In the proposed study we aim to overcome these technical obstacles and develop a simple point of care assay by integrating a novel Tumor Cell activation Aptamer Reporting system TCAR and innovative Spinning Disc Imaging Technology iSDI In contrast to current antibody mediated multi step tests the TCAR system will be able to selectively highlight CTCs through natural cellular processes in whole blood within minutes using a single step reaction In addition TCAR will provide no background or off target signals and will not require a post labeling cell wash The iSDI technology will detect CTCs in a high speed manner and record high resolution images similar to a Blu ray disc player reading bits on disc Compared to conventional automated fluorescence microscopes the iSDI system is superior in sensitivity speed and operates at a lower cost We hypothesize that this assay will be able to detect an accurate number of CTCs within minutes in whole blood samples through a single step reaction which will eliminate potential loss of and damage to CTCs in the samples To test our hypothesis three aims are proposed We will optimize the TCAR system containing aptamer probes specific for EpCAM to selectively highlight carcinoma tumor cells in whole blood Aim while constructing and validating the iSDI system for coating scanning and imaging cells completely hands free in minutes Aim In Aim we will integrate the TCAR and iSDI systems develop a point of care assay for rapid detection of CTCs and validate the performance using tumor cells in normal human blood samples We predict that this simple assay will provide high definition morphology of CTCs along with their fluorescence identity in one step within minutes PUBLIC HEALTH RELEVANCE A simple assay system for rapid detection of circulating tumor cells The successful development and validation of the proposed TCAR iSDI system has the potential to significantly improve cancer progression and treatment evaluations and therefore improve outcomes in this large patient population

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government